Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRIS-IPF Phase 2a study of PLN-74809 in idiopathic pulmonary fibrosis
2019-002709-23Phase 2Unknown
- Sponsor
- Pliant Therapeutics
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing PLN-74809 dose-ranging with Placebo (2 arms). Primary endpoint: Primary Safety Endpoint. Status: unknown.
02
Drugs
bexotegrast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2019-002709-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002709-23.